Miniature kidneys could accelerate new treatments for acute kidney injury

Researchers from Monash University in Australia have created miniature human kidneys using stem cells, a breakthrough that could speed up the discovery of treatments for acute kidney injury (AKI). AKI is a sudden loss of kidney function that can lead to severe illness and long-term damage if not treated promptly. The microscopic, living models, detailed in a Genome Medicine study, capture the critical elements of AKI, allowing scientists to examine why certain kidney cells heal while others suffer lasting harm that can contribute to chronic kidney disease.

Dr. Alexander Combes, the lead researcher and head of the Development and Disease Laboratory, explained that the new model provides an innovative approach to studying kidney injury and evaluating potential treatments. AKI can arise during major surgery, organ transplantation, or due to certain medications like chemotherapy. Combes and his team aim to use these miniature kidneys to identify therapies that can safeguard the kidney or enhance recovery after injury.

Professor John Kanellis, director of nephrology at Monash Health, highlighted that AKI affects around 20% of hospital admissions, underscoring the pressing need for improved treatments. Human kidney organoids offer a controlled, human-relevant model to study AKI, revealing how different kidney cells respond to injury, recover, or persistently damage.

These models could pinpoint new therapeutic targets to enhance recovery and prevent the progression to chronic kidney disease. The development of these miniature kidneys could lead to the rapid screening of existing medications, potentially shortening the time it takes for new treatments to reach clinical use by leveraging established safety and clinical data.